,address1,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,totalDebt,quickRatio,currentRatio,returnOnAssets,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,1500 District Avenue,Burlington,MA,01803,United States,617 600 7373,https://www.minervaneurosciences.com,Biotechnology,Healthcare,"Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.",9,"{'maxAge': 1, 'name': 'Dr. Remy  Luthringer Ph.D.', 'age': 61, 'title': 'Exec. Chairman & CEO', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 853582, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,7.86,7.92,7.78,7.92,7.86,7.92,7.78,7.92,0.0,0.169778,-2.261628,11093,11093,940093,30870,30870,7.65,8.57,1000,1300,54408732,1.26,14.7,9.2062,5.04396,0.0,0.0,USD,2611987,0.0,5435625,6993410,80283,122723,1690761600,1693440000,0.0115,0.26182,0.30936,2.27,0.0196,-1.789,1672444800,1703980800,1688083200,-26788980,-4.97,-3.44,NCM,EQUITY,NERV,NERV,"Minerva Neurosciences, Inc","Minerva Neurosciences, Inc.",1404221400,America/New_York,EDT,-14400000,7.78,11.0,11.0,11.0,11.0,3.0,hold,1,51796712,7.407,0,27.15,27.375,-0.19063,-16070111,-17631352,0.0,0.0,0.0,USD,
1,1500 District Avenue,Burlington,MA,01803,United States,617 600 7373,https://www.minervaneurosciences.com,Biotechnology,Healthcare,"Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.",9,"{'maxAge': 1, 'name': 'Mr. Geoffrey Robin Race F.C.M.A., FCMA, M.B.A., MBA', 'age': 61, 'title': 'Pres', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 628463, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,7.86,7.92,7.78,7.92,7.86,7.92,7.78,7.92,0.0,0.169778,-2.261628,11093,11093,940093,30870,30870,7.65,8.57,1000,1300,54408732,1.26,14.7,9.2062,5.04396,0.0,0.0,USD,2611987,0.0,5435625,6993410,80283,122723,1690761600,1693440000,0.0115,0.26182,0.30936,2.27,0.0196,-1.789,1672444800,1703980800,1688083200,-26788980,-4.97,-3.44,NCM,EQUITY,NERV,NERV,"Minerva Neurosciences, Inc","Minerva Neurosciences, Inc.",1404221400,America/New_York,EDT,-14400000,7.78,11.0,11.0,11.0,11.0,3.0,hold,1,51796712,7.407,0,27.15,27.375,-0.19063,-16070111,-17631352,0.0,0.0,0.0,USD,
2,1500 District Avenue,Burlington,MA,01803,United States,617 600 7373,https://www.minervaneurosciences.com,Biotechnology,Healthcare,"Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.",9,"{'maxAge': 1, 'name': 'Mr. Frederick W. Ahlholm CPA, CPA', 'age': 56, 'title': 'Sr. VP, CFO & Sec.', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 567487, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,7.86,7.92,7.78,7.92,7.86,7.92,7.78,7.92,0.0,0.169778,-2.261628,11093,11093,940093,30870,30870,7.65,8.57,1000,1300,54408732,1.26,14.7,9.2062,5.04396,0.0,0.0,USD,2611987,0.0,5435625,6993410,80283,122723,1690761600,1693440000,0.0115,0.26182,0.30936,2.27,0.0196,-1.789,1672444800,1703980800,1688083200,-26788980,-4.97,-3.44,NCM,EQUITY,NERV,NERV,"Minerva Neurosciences, Inc","Minerva Neurosciences, Inc.",1404221400,America/New_York,EDT,-14400000,7.78,11.0,11.0,11.0,11.0,3.0,hold,1,51796712,7.407,0,27.15,27.375,-0.19063,-16070111,-17631352,0.0,0.0,0.0,USD,
3,1500 District Avenue,Burlington,MA,01803,United States,617 600 7373,https://www.minervaneurosciences.com,Biotechnology,Healthcare,"Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.",9,"{'maxAge': 1, 'name': 'Mr. Joseph  Reilly', 'age': 47, 'title': 'Sr. VP & COO', 'yearBorn': 1975, 'fiscalYear': 2016, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,7.86,7.92,7.78,7.92,7.86,7.92,7.78,7.92,0.0,0.169778,-2.261628,11093,11093,940093,30870,30870,7.65,8.57,1000,1300,54408732,1.26,14.7,9.2062,5.04396,0.0,0.0,USD,2611987,0.0,5435625,6993410,80283,122723,1690761600,1693440000,0.0115,0.26182,0.30936,2.27,0.0196,-1.789,1672444800,1703980800,1688083200,-26788980,-4.97,-3.44,NCM,EQUITY,NERV,NERV,"Minerva Neurosciences, Inc","Minerva Neurosciences, Inc.",1404221400,America/New_York,EDT,-14400000,7.78,11.0,11.0,11.0,11.0,3.0,hold,1,51796712,7.407,0,27.15,27.375,-0.19063,-16070111,-17631352,0.0,0.0,0.0,USD,
4,1500 District Avenue,Burlington,MA,01803,United States,617 600 7373,https://www.minervaneurosciences.com,Biotechnology,Healthcare,"Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.",9,"{'maxAge': 1, 'name': 'Mr. William B. Boni', 'age': 70, 'title': 'VP of Investor Relations & Corp. Communications', 'yearBorn': 1952, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,7.86,7.92,7.78,7.92,7.86,7.92,7.78,7.92,0.0,0.169778,-2.261628,11093,11093,940093,30870,30870,7.65,8.57,1000,1300,54408732,1.26,14.7,9.2062,5.04396,0.0,0.0,USD,2611987,0.0,5435625,6993410,80283,122723,1690761600,1693440000,0.0115,0.26182,0.30936,2.27,0.0196,-1.789,1672444800,1703980800,1688083200,-26788980,-4.97,-3.44,NCM,EQUITY,NERV,NERV,"Minerva Neurosciences, Inc","Minerva Neurosciences, Inc.",1404221400,America/New_York,EDT,-14400000,7.78,11.0,11.0,11.0,11.0,3.0,hold,1,51796712,7.407,0,27.15,27.375,-0.19063,-16070111,-17631352,0.0,0.0,0.0,USD,
5,1500 District Avenue,Burlington,MA,01803,United States,617 600 7373,https://www.minervaneurosciences.com,Biotechnology,Healthcare,"Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.",9,"{'maxAge': 1, 'name': 'Prof. Michael  Davidson M.D.', 'age': 72, 'title': 'Chief Medical Officer', 'yearBorn': 1950, 'fiscalYear': 2021, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,7.86,7.92,7.78,7.92,7.86,7.92,7.78,7.92,0.0,0.169778,-2.261628,11093,11093,940093,30870,30870,7.65,8.57,1000,1300,54408732,1.26,14.7,9.2062,5.04396,0.0,0.0,USD,2611987,0.0,5435625,6993410,80283,122723,1690761600,1693440000,0.0115,0.26182,0.30936,2.27,0.0196,-1.789,1672444800,1703980800,1688083200,-26788980,-4.97,-3.44,NCM,EQUITY,NERV,NERV,"Minerva Neurosciences, Inc","Minerva Neurosciences, Inc.",1404221400,America/New_York,EDT,-14400000,7.78,11.0,11.0,11.0,11.0,3.0,hold,1,51796712,7.407,0,27.15,27.375,-0.19063,-16070111,-17631352,0.0,0.0,0.0,USD,
6,1500 District Avenue,Burlington,MA,01803,United States,617 600 7373,https://www.minervaneurosciences.com,Biotechnology,Healthcare,"Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.",9,"{'maxAge': 1, 'name': 'Dr. Ramana  Kuchibhatla Ph.D.', 'title': 'Sr. VP and Head of R&D', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,7.86,7.92,7.78,7.92,7.86,7.92,7.78,7.92,0.0,0.169778,-2.261628,11093,11093,940093,30870,30870,7.65,8.57,1000,1300,54408732,1.26,14.7,9.2062,5.04396,0.0,0.0,USD,2611987,0.0,5435625,6993410,80283,122723,1690761600,1693440000,0.0115,0.26182,0.30936,2.27,0.0196,-1.789,1672444800,1703980800,1688083200,-26788980,-4.97,-3.44,NCM,EQUITY,NERV,NERV,"Minerva Neurosciences, Inc","Minerva Neurosciences, Inc.",1404221400,America/New_York,EDT,-14400000,7.78,11.0,11.0,11.0,11.0,3.0,hold,1,51796712,7.407,0,27.15,27.375,-0.19063,-16070111,-17631352,0.0,0.0,0.0,USD,
